Abstract
Background:
Head and neck cancer (HNC) ranks the fourth leading malignancy and cancer death in male population in Taiwan. Despite recent therapeutic advances, the prognosis for HNC patients is still dismal. New strategies are urgently needed to improve the chemosensitization to conventional chemotherapeutic drugs and clinical responses of HNC patients. Studies have demonstrated that topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) is being used in the treatment of various human premalignant and malignant lesions with some encouraging clinical outcomes. However, the molecular mechanisms of ALA-PDT in the therapeutic effect in HNC tumorigenesis and whether ALA-PDT as chemosensitizer for HNC treatment remain unclear. Accumulating data support cancer stem cells (CSCs) contributes chemo-resistance in HNC. Based on the previous studies, the purpose of the study is to investigate the effect of ALA-PDT on CSCs and chemosensitization property in HNC.
Methodology/principal finding:
CSCs marker ALDH1 activity of HNC cells with ALA-PDT treatment as assessed by the Aldefluor assay flow cytometry analysis. Secondary Sphere-forming self-renewal, stemness markers expression, and invasiveness of HNC-CSCs with ALA-PDT treatment were presented. We observed that the treatment of ALA-PDT significantly down-regulated the ALDH1 activity and CD44 positivity of HNC-CSCs. Moreover, ALA-PDT reduced self-renewal property and stemness signatures expression (Oct4 and Nanog) in sphere-forming HNC-CSCs. ALA-PDT sensitized highly tumorigenic HNC-CSCs to conventional chemotherapies. Lastly, synergistic effect of ALA-PDT and Cisplatin treatment attenuated invasiveness/colongenicity property in HNC-CSCs.
Conclusion/significance:
Our results provide insights into the clinical prospect of ALA-PDT as a potential chemo-adjuvant therapy against head and neck cancer through eliminating CSCs property.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aldehyde Dehydrogenase 1 Family
-
Aminolevulinic Acid / pharmacology*
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism
-
Cell Line, Tumor
-
Cell Transformation, Neoplastic / drug effects
-
Cell Transformation, Neoplastic / genetics
-
Cell Transformation, Neoplastic / metabolism
-
Cell Transformation, Neoplastic / pathology
-
Cisplatin / pharmacology
-
Drug Resistance, Neoplasm / drug effects*
-
Drug Resistance, Neoplasm / genetics
-
Drug Synergism
-
Gene Expression Regulation, Neoplastic
-
Head and Neck Neoplasms / drug therapy*
-
Head and Neck Neoplasms / genetics
-
Head and Neck Neoplasms / metabolism
-
Head and Neck Neoplasms / pathology
-
Homeodomain Proteins / genetics
-
Homeodomain Proteins / metabolism
-
Humans
-
Hyaluronan Receptors / genetics
-
Hyaluronan Receptors / metabolism
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / genetics
-
Isoenzymes / metabolism
-
Nanog Homeobox Protein
-
Neoplastic Stem Cells / drug effects*
-
Neoplastic Stem Cells / metabolism
-
Neoplastic Stem Cells / pathology
-
Octamer Transcription Factor-3 / genetics
-
Octamer Transcription Factor-3 / metabolism
-
Photochemotherapy*
-
Photosensitizing Agents / pharmacology*
-
Primary Cell Culture
-
Radiation-Sensitizing Agents / pharmacology
-
Retinal Dehydrogenase / antagonists & inhibitors
-
Retinal Dehydrogenase / genetics
-
Retinal Dehydrogenase / metabolism
Substances
-
Biomarkers, Tumor
-
CD44 protein, human
-
Homeodomain Proteins
-
Hyaluronan Receptors
-
Isoenzymes
-
NANOG protein, human
-
Nanog Homeobox Protein
-
Octamer Transcription Factor-3
-
POU5F1 protein, human
-
Photosensitizing Agents
-
Radiation-Sensitizing Agents
-
Aminolevulinic Acid
-
Aldehyde Dehydrogenase 1 Family
-
ALDH1A1 protein, human
-
Retinal Dehydrogenase
-
Cisplatin
Grants and funding
This study is supported by research grant from National Science Council (100-2632-B-040-001-MY3, 101-2314-B-040-016, 102-2628-B-040 -001 -MY3).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.